Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Shares Issued (2020 - 2025)

Summit Therapeutics (SMMT) has disclosed Shares Issued for 6 consecutive years, with $492.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 13.33% year-over-year to $492.7 million, compared with a TTM value of $500.0 million through Dec 2025, up 14.99%, and an annual FY2025 reading of $500.0 million, up 14.99% over the prior year.
  • Shares Issued was $492.7 million for Q4 2025 at Summit Therapeutics, up from $5.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $492.7 million in Q4 2025 and bottomed at -$651000.0 in Q2 2023.
  • Average Shares Issued over 5 years is $52.2 million, with a median of $568000.0 recorded in 2023.
  • The sharpest move saw Shares Issued tumbled 248.13% in 2023, then soared 134500.31% in 2024.
  • Year by year, Shares Issued stood at $1.2 million in 2021, then crashed by 91.48% to $104000.0 in 2022, then skyrocketed by 210.58% to $323000.0 in 2023, then skyrocketed by 134500.31% to $434.8 million in 2024, then grew by 13.33% to $492.7 million in 2025.
  • Business Quant data shows Shares Issued for SMMT at $492.7 million in Q4 2025, $5.3 million in Q2 2025, and $2.0 million in Q1 2025.